An antibody–drug conjugate in place of chemotherapy nearly tripled progression-free survival in PD-L1-negative NSCLC

Design

Phase 3, randomised, open-label; interim analysis

Population

455 patients with untreated PD-L1 <1% non-squamous NSCLC without targetable alterations

Primary outcome

Progression-free survival by blinded central review

Effect

Median 15.0 vs 5.7 months; HR 0.49 (0.36–0.65)

OptiTROP-Lung06, an open-label phase 3 trial published in NEJM on 25 October, randomised 455 patients with untreated advanced non-squamous NSCLC, no targetable alteration and PD-L1 below 1%. They received the TROP2-directed antibody–drug conjugate sacituzumab tirumotecan plus pembrolizumab, or the standard platinum–pemetrexed plus pembrolizumab.

At a median follow-up of 9.7 months, median progression-free survival was 15.0 months against 5.7 months (HR 0.49, 95% CI 0.36–0.65). Response rates were similar (50% vs 47%), but responses lasted twice as long (13.6 vs 6.8 months). Overall survival was immature (HR 0.58, 0.38–0.88). Grade 3 or worse adverse events were less frequent with the conjugate (47.6% vs 60.6%); stomatitis was common but mostly mild.

PD-L1-negative disease is where immunotherapy alone helps least, so a chemotherapy-free partner for pembrolizumab matters. Short follow-up, an open-label design, industry funding and a likely mainly Chinese population all limit what can be concluded. The drug is not approved in India.

• Sacituzumab tirumotecan is investigational outside China and not approved by CDSCO.
• Platinum–pemetrexed with pembrolizumab remains standard first-line for PD-L1-negative non-squamous NSCLC.
• Stomatitis is the characteristic toxicity of TROP2 conjugates; plan mouth care from the first cycle if they are used.
• Await overall survival data before treating this as a new standard.

Why it matters

It challenges platinum doublets as the necessary partner for immunotherapy in the subgroup that benefits least from immunotherapy alone.

Don't overread it

Interim progression-free survival with immature overall survival; this is not yet a survival benefit.

The statistics, in plain English

The overall survival hazard ratio of 0.58 looks favourable, but it is based on few deaths at under a year of follow-up and was not the primary endpoint; such early estimates often shrink.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.